Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea

Apr 02 2019

• By Joseph Haas

Medical photo Age-related macular degeneration (AMD)

Related Content

Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab

Nov 12 2017

Regeneron's Less Frequent Eylea Dosing Makes Late Sprint Across FDA Finish Line

Aug 17 2018

Allergan's Abicipar Effective With Fewer Injections, But More Inflammation In AMD

Jul 20 2018

Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Feb 04 2017

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

Mar 07 2019

Related Companies

Allergan plc

Molecular Partners AG

Roche Holding AG

Novartis AG

Amgen, Inc.

Regeneron Pharmaceuticals, Inc.

Bayer AG

Graybug Vision, Inc.

Additional Topics

Clinical Trials Commercial Drug Safety Business Strategies Ophthalmic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.